Literature DB >> 22203563

Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran.

Amin Talebi Bezmin Abadi1, Tarang Taghvaei, Ashraf Mohabbati Mobarez, Beth M Carpenter, D Scott Merrell.   

Abstract

The purpose of this study was to evaluate the primary resistance rates of recent clinical Helicobacter pylori isolates to the most commonly used antibiotics in Iran. Two hundreds and ten patients presenting with gastric maladies between January and July of 2009 were enrolled in this study. Endoscopy was performed, and biopsy specimens were collected from each patient for subsequent bacterial culture of H. pylori. Single colony isolates from each patient were then used for antimicrobial susceptibility testing. The disk diffusion method was used to determine susceptibility patterns. One hundred and ninety-seven of the patients were H. pylori positive (93.8%). The rates of resistance to tetracycline, amoxicillin, ciprofloxacin, metronidazole, clarithromycin, and furizoladone were 37.1%, 23.9%, 34.5%, 65.5%, 45.2%, and 61.4%, respectively. A significant association between amoxicillin resistance and disease state (P<0.05) was identified. Furthermore, some double, triple, quadruple, and quintuple combinations of antibiotic resistance were found to be associated with disease state. This study evaluated the prevalence of H. pylori resistance to the most commonly prescribed antibiotics used in Iran and showed that resistance rates were generally higher than previously reported. This data adds to the growing body of evidence that suggests there is increasing antibiotic resistance among H. pylori isolates, which likely is responsible for the decreasing efficacy of anti-H. pylori therapy at the local and global level. Hence, there is a need for continued monitoring of resistance patterns, especially at the local level, and for incorporation of that information into treatment regimens for H. pylori infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22203563      PMCID: PMC3275342          DOI: 10.1007/s12275-011-1170-6

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  32 in total

1.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

2.  Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease.

Authors:  R Malekzadeh; R Ansari; H Vahedi; F Siavoshi; B Z Alizadeh; M R Eshraghian; A Vakili; M Saghari; S Massarrat
Journal:  Aliment Pharmacol Ther       Date:  2000-03       Impact factor: 8.171

3.  Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.

Authors:  H Fakheri; R Malekzadeh; S Merat; M Khatibian; A Fazel; B Z Alizadeh; S Massarrat
Journal:  Aliment Pharmacol Ther       Date:  2001-03       Impact factor: 8.171

4.  Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran.

Authors:  Shohreh Farshad; Abdolvahab Alborzi; Aziz Japoni; Reza Ranjbar; Kazem Hosseini Asl; Parisa Badiee; Maneli Amin Shahidi; Marziyeh Hosseini
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

5.  Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection.

Authors:  A M Segura; O Gutiérrez; W Otero; A Angel; R M Genta; D Y Graham
Journal:  Aliment Pharmacol Ther       Date:  1997-06       Impact factor: 8.171

6.  A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer.

Authors:  A Leodolter; M Kulig; H Brasch; W Meyer-Sabellek; S N Willich; P Malfertheiner
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

7.  Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States.

Authors:  M S Osato; R Reddy; S G Reddy; R L Penland; H M Malaty; D Y Graham
Journal:  Arch Intern Med       Date:  2001-05-14

8.  Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000.

Authors:  Kathlen Wolle; Andreas Leodolter; Peter Malfertheiner; Wolfgang König
Journal:  J Med Microbiol       Date:  2002-08       Impact factor: 2.472

9.  Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents.

Authors:  Lyudmila Boyanova; Ivan Mitov
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

Review 10.  Gastric cancer in Iran: epidemiology and risk factors.

Authors:  Reza Malekzadeh; Mohammad H Derakhshan; Zinab Malekzadeh
Journal:  Arch Iran Med       Date:  2009-11       Impact factor: 1.354

View more
  25 in total

Review 1.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

2.  Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization.

Authors:  Amin Talebi Bezmin Abadi
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

Review 3.  Second and third line treatment options for Helicobacter pylori eradication.

Authors:  Mingjun Song; Tiing Leong Ang
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 4.  Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.

Authors:  Sinéad M Smith; Colm O'Morain; Deirdre McNamara
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 5.  Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.

Authors:  Reza Ghotaslou; Hamed Ebrahimzadeh Leylabadlo; Yalda Mohammadzadeh Asl
Journal:  World J Methodol       Date:  2015-09-26

Review 6.  Vaccine against Helicobacter pylori: Inevitable approach.

Authors:  Amin Talebi Bezmin Abadi
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

Review 7.  Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication.

Authors:  Sang-Ho Park; Napapan Kangwan; Jong-Min Park; Eun-Hee Kim; Ki Baik Hahm
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

8.  Comparing the efficacy of four different protocols for eradicating of Helicobacter pylori infection in Ahvaz, southwest Iran.

Authors:  Abdolrahim Masjedizadeh; Narjes Zaeemzadeh; Seyyed Ali Mard; Ghazal Salehi Vanani
Journal:  Prz Gastroenterol       Date:  2015-02-10

9.  Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland.

Authors:  Elżbieta Karczewska; Karolina Klesiewicz; Iwona Skiba; Izabela Wojtas-Bonior; Edward Sito; Krzysztof Czajecki; Małgorzata Zwolińska-Wcisło; Alicja Budak
Journal:  Gastroenterol Res Pract       Date:  2012-05-27       Impact factor: 2.260

10.  Platelet Count Response to Helicobacter pylori Eradication in Iranian Patients with Idiopathic Thrombocytopenic Purpura.

Authors:  Mehrdad Payandeh; Nasrollah Sohrabi; Mohammad Erfan Zare; Atefeh Nasir Kansestani; Amir Hossein Hashemian
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-08-10       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.